Clinical trial of ticagrelor tablets combined with aspirin tablets in the treatment of patients with ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary intervention
10.13699/j.cnki.1001-6821.2019.07.004
- VernacularTitle:替格瑞洛片联合阿司匹林片用于经皮冠状动脉介入术的急性ST段抬高型心肌梗死患者的临床研究
- Author:
Yan-Li DONG
1
;
Shu-Juan DONG
Author Information
1. 郑州市第二人民医院 心血管内科
- Keywords:
ticagrelor tablet;
clopidogrel tablet;
aspirin tablet;
acute ST-segment elevation myocardial infarction;
safety evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2019;35(7):614-616
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of ticagrelor tablets combined with aspirin tablets in patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI) . Methods A total of 426 patients with STEMI treated with PCI were randomly divided into control and treatment groups with 213 cases per group. Control group was orally given the loading dose of clopidogrel 600 mg + aspirin 300 mg before PCI, followed by oral clopidogrel 75 mg per time, qd + aspirin 100 mg per time, qd, after operation. Treatment group was given orally ticagrelor with the loading dose of 180 mg + aspirin 300 mg before PCI, followed ticagrelor 90 mg per time orally, bid + aspirin 100 mg per time, qd, after operation.Two groups were treated for 30 days. The red blood cell distribution width (RDW) , neutrophil/lymphocyte ratio (NLR) , platelet/lymphocyte ratio (PLR) and adverse drug reactions were compared between two groups. Results After PCI 30 days, the main indexes of treatment and control groups were compared: RDW were (14. 85 ± 0. 95) ％ and (11. 48 ± 1. 43) ％, NLR were (2. 98 ± 0. 98) ％ and (2. 09 ± 1. 68) ％, PLR were (120. 34 ± 13. 88) ％ and (131. 36 ± 12. 96) ％, the differences were statistically significant (all P < 0. 05) . The adverse drug reactions of treatment group were dizziness, gastrointestinal bleeding and serum creatinine rise, which in control group were diarrhea, gastrointestinal bleeding, headache, nausea and vomiting. The total incidences of adverse drug reactions in the treatment and control groups were 5. 16％ and9. 86％ with significant difference (P < 0. 05) . Conclusion Ticagrelor tablets combined with aspirin tablets have a definitive clinical efficacy and safety in the treatment of patients with STEMI treated with PCI.
